INIS
patients
100%
kidneys
90%
diseases
72%
cardiovascular diseases
54%
phosphates
36%
medicine
27%
nicotinamide
27%
lanthanum carbonates
18%
clinical trials
18%
binders
18%
metabolism
18%
pathogenesis
18%
schools
9%
bile acids
9%
public health
9%
phenotype
9%
transport
9%
universities
9%
levels
9%
strains
9%
risks
9%
minerals
9%
biological markers
9%
comparative evaluations
9%
interventions
9%
proposals
9%
assessments
9%
fibroblasts
9%
awards
9%
management
9%
hypothesis
9%
growth factors
9%
metabolites
9%
research programs
9%
Medicine and Dentistry
Chronic Kidney Disease
81%
Patient
63%
Cardiovascular Disease
54%
Inpatient
36%
Clinical Trial
36%
Placebo
36%
Nicotinamide
27%
Pathogenesis
18%
Lanthanum Carbonate
18%
Fibroblast Growth Factor 23
18%
Phosphate
18%
Mentoring
18%
Athletic Training
18%
Mineral Metabolism
9%
Bile Acid
9%
Metabolite
9%
Biological Marker
9%
Blood Vessel Calcification
9%
Nephrology
9%
Leadership
9%
Metabolism
9%
Calcification
9%
Methamidophos
9%
Phosphate Transport
9%
Deoxycholic Acid
9%
Phenotype
9%
Phosphate Binder
9%
Cohort Analysis
9%
Cohort Effect
9%
Assessment
9%
Serum
9%
Skill
9%
Division
9%
Gut
9%
Resident
9%
Medical Student
9%
Association
9%
Kidney
9%
Health
9%
Public Health
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
81%
Polyimide
36%
Nicotinamide
27%
Phosphate
22%
Fibroblast Growth Factor 23
18%
Pathogenesis
18%
Observational Study
18%
Lanthanum Carbonate
18%
Deoxycholic Acid
9%
Blood Vessel Calcification
9%
Phosphate Binding Agent
9%
Biological Marker
9%
Epidemiology
9%
Bile Acid
9%
Methamidophos
9%
Calcification
9%
Fibroblast Growth Factor
9%